Literature DB >> 8255982

Clinical overview on moclobemide.

J W Tiller1.   

Abstract

1. Moclobemide is a novel benzamide reversible inhibitor of monoamine oxidase A and has clinical efficacy in a wide spectrum of depressive illness including endogenous and non-endogenous depression, in younger adults and in the elderly. 2. Comparisons have shown similar efficacy to all main classes of antidepressants and much greater tolerability and safety in overdose than tricyclic antidepressants. Clinically, it is neither sedative nor alerting. 3. There is no need for dietary restrictions for patients on moclobemide on a normal diet, and drug interactions are few and usually mild. Specific cautions are noted with pethidine and with selective serotonin re-uptake inhibitor antidepressants. 4. Moclobemide is a useful addition to the range of antidepressants in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255982     DOI: 10.1016/0278-5846(93)90054-v

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

1.  Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.

Authors:  Joo-Youn Cho; Kyung-Sang Yu; In-Jin Jang; Byung-Hwan Yang; Sang-Goo Shin; Dong-Seok Yim
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

Review 2.  Antidepressant toxicity and the need for identification and concentration monitoring in overdose.

Authors:  B M Power; L P Hackett; L J Dusci; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

Review 3.  A risk-benefit assessment of moclobemide in the treatment of depressive disorders.

Authors:  T R Norman; G D Burrows
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.